Circulatory system

Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors

Retrieved on: 
Monday, July 24, 2023
Inflammation, PDMA, Amgen, BS, Sabine Lisicki, Therapy, State University of New York, Arena Pharmaceuticals, Compensation, State university system, EMA, Economics, Acquisition, Immunology, Regeneron Pharmaceuticals, FDA, Pfizer, Pharmaceutical industry, Pain, Circulatory system

PONTE VEDRA, Fla., July 24, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., ("Cadrenal" or the "Company") (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced the appointment of Robert Lisicki to its Board of Directors and Compensation and Nomination/Governance Committees.

Key Points: 
  • PONTE VEDRA, Fla., July 24, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., ("Cadrenal" or the "Company") (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced the appointment of Robert Lisicki to its Board of Directors and Compensation and Nomination/Governance Committees.
  • "I look forward to leaning on his executive experience and commercial vision as a member of the Cadrenal board."
  • "I believe Cadrenal Therapeutics is developing a novel and potentially paradigm-changing therapeutic," said Robert Lisicki.
  • Lisicki will occupy a newly created seat on the Cadrenal Board of Directors.

Microbot Medical Expands its Physician Support with the Addition of Leading Italian Interventional Radiologist Irene Bargellini, M.D., to its Scientific Advisory Board

Retrieved on: 
Tuesday, July 11, 2023
SAB, EASL, Radiation, Society, European Society of Radiology, ZEUS robotic surgical system, ESR, Diagnosis, Editorial board, Woman, Abdominal Radiology, CIRSE, ILCA, Gastrointestinal tract, Interventional radiology, MD, Circulatory system, Executive Committee, Cardiovascular and Interventional Radiological Society of Europe, Health, Medical imaging, Radiology, Liver

Dr. Bargellini is the latest expansion of Microbot’s global presence with highly esteemed medical experts in large addressable markets.

Key Points: 
  • Dr. Bargellini is the latest expansion of Microbot’s global presence with highly esteemed medical experts in large addressable markets.
  • Dr. Bargellini’s primary clinical and scientific focus is on oncologic imaging and interventional oncology, with reference to liver imaging and liver tumors’ loco-regional and systemic therapies.
  • “It is encouraging that leading interventional radiologists continue to join Microbot as it embarks on the steps towards the commercialization of the system,” commented Eyal Morag, MD, Chief Medical Officer.
  • She serves as reviewer of several national and international journals and is Member of the Editorial Board of European Radiology and Cardiovascular and Interventional Radiology journals.

SS Innovations International, Inc. to Present at the Emerging Growth Conference on Wednesday July 12, 2023

Retrieved on: 
Monday, July 10, 2023
Well, Interactivity, Million Pound Menu, Adviser, SSI, Circulatory system, OTC, Growth, Urology, Conference, General surgery, Thorax, Gynaecology

FORT LAUDERDALE, FL, July 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that it has been invited to present at the Emerging Growth Conference on Wednesday July 12, 2023 at 10:50 am ET.

Key Points: 
  • SS Innovations Invites Individual and Institutional Investors as Well as Advisors and Analysts, to Attend Its Real-time, Interactive Presentation at the Emerging Growth Conference
    FORT LAUDERDALE, FL, July 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that it has been invited to present at the Emerging Growth Conference on Wednesday July 12, 2023 at 10:50 am ET.
  • The Emerging Growth Conference is a live, interactive online event that gives existing shareholders and the investment community the opportunity to interact in real time with Dr. Sudhir Srivastava, CEO, Chairman and Founder of SS Innovations and a pioneer in robotic cardiothoracic surgery.
  • Please submit your questions in advance to [email protected] or ask your questions during the event and Dr. Srivastava will respond to as many as possible.
  • Please register here to ensure you are able to attend the conference and receive any updates that are released:

Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Retrieved on: 
Friday, June 30, 2023
Biotechnology, FDA, Health, Genetics, Pharmaceutical, Prescription Drug User Fee Act, Nyctalopia, Therapy, Register, Premedication, Serum, New Drug Application, Vitamin A deficiency, Vitamin A, Federal, IRR, Abdominal pain, Medication, Amyloidosis, Back pain, ATTR, Patient, Risk, Paracetamol, Circulatory system, Nausea, Periodic breathing, RNA interference, Cardiomyopathy, Polyneuropathy, Headache, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, RDA, Food, Dietary supplement

As previously announced, the FDA has set an action date of October 8, 2023 under the Prescription Drug User Fee Act.

Key Points: 
  • As previously announced, the FDA has set an action date of October 8, 2023 under the Prescription Drug User Fee Act.
  • An advanced display of the public notice is available in the Federal Register here .
  • Patisiran is the established name for ONPATTRO®, which is currently approved by the U.S. FDA for the treatment of the polyneuropathy of hereditary ATTR amyloidosis in adults.
  • ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Microbot Medical Announces Multiple Peer Reviewed Abstracts Accepted by The Cardiovascular and Interventional Radiological Society of Europe

Retrieved on: 
Friday, June 16, 2023
Abstract, KOL, Cardiovascular and Interventional Radiological Society of Europe, Validation, Investigation, Disposable product, ICR, ZEUS robotic surgical system, Internet, Clinical trial, Compact, CIRSE, Circulatory system, V&V, FIH, IDE, FDA, Conference, Investigational device exemption, Safety, Medical device, Robotics

Further displaying their positive experiences and satisfaction, the Company has been informed that two peer-reviewed abstracts have been accepted to be presented at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).

Key Points: 
  • Further displaying their positive experiences and satisfaction, the Company has been informed that two peer-reviewed abstracts have been accepted to be presented at the Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
  • In addition, one of the abstracts was accepted as an oral presentation.
  • These peer-reviewed abstracts follow the highly successful extended joint pre-clinical animal studies held at leading European-based research labs by a team of seven renowned European interventional radiologists.
  • We believe that the current and future peer-reviewed data will accelerate adoption of LIBERTY once commercialized," said Dr. Eyal Morag, Chief Medical Officer of Microbot Medical.

SS Innovations International Presents at MoneyShow Virtual Expo

Retrieved on: 
Friday, June 9, 2023
Infection, Availability, Surgeon, Mantra, Million Pound Menu, SSI, Pain, Risk, Circulatory system, OTC, Urology, General surgery, Dentistry, Thorax, Gynaecology

FORT LAUDERDALE, FL, June 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that it presented at the MoneyShow Virtual Expo for Accredited Investors held on June 6-7, 2023.

Key Points: 
  • “The Progression of Surgical Robotics: Introducing the SSi Mantra System” Video Presentation Now Available for Viewing
    FORT LAUDERDALE, FL, June 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that it presented at the MoneyShow Virtual Expo for Accredited Investors held on June 6-7, 2023.
  • Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, and a pioneer in robotic cardiothoracic surgery, gave a presentation introducing the Company’s flagship SSI Mantra surgical robotic system.
  • The innovative system is currently being utilized to perform successfully in a wide array of surgical specialties including Cardiovascular, Thoracic, Head and Neck, Gynecology, Urology, General Surgery, and very complex robotic cancer operations.
  • To date, more than 200 surgeries and 35 different types of surgical procedures across every specialty have been performed using the SSi Mantra system.

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc

Retrieved on: 
Thursday, June 1, 2023
IL-12, Interleukin, IRS, Drug development, Lead, Bristol Myers Squibb, Immunotherapy, IL-2, ALKS, Circulatory system, Form 10-K, Fibrosis, Pharmaceutical Research and Manufacturers of America, Merck, BMS, Imperial College London, Management, Nursing, Alkermes, Chemistry

DUBLIN, June 1, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that Caroline J. Loew, Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc (Mural Oncology), the new independent public company to be established upon the planned separation of Alkermes' oncology business. Dr. Loew will join Alkermes in June as a strategic advisor and transition to CEO of Mural Oncology upon completion of the separation. 

Key Points: 
  • DUBLIN, June 1, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that Caroline J. Loew, Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc (Mural Oncology), the new independent public company to be established upon the planned separation of Alkermes' oncology business.
  • Dr. Loew will join Alkermes in June as a strategic advisor and transition to CEO of Mural Oncology upon completion of the separation.
  • "I'm delighted that we have appointed someone of Dr. Loew's caliber and scientific pedigree for the Mural Oncology CEO role.
  • Upon completion of the planned separation, Mural Oncology plc is expected to be a Nasdaq listed company, trading under the ticker symbol MURA.

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc

Retrieved on: 
Thursday, June 1, 2023
IL-12, Interleukin, IRS, Drug development, Lead, Bristol Myers Squibb, Immunotherapy, IL-2, ALKS, Circulatory system, Form 10-K, Fibrosis, Pharmaceutical Research and Manufacturers of America, Merck, BMS, Imperial College London, Management, Nursing, Alkermes, Chemistry

DUBLIN, June 1, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that Caroline J. Loew, Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc (Mural Oncology), the new independent public company to be established upon the planned separation of Alkermes' oncology business. Dr. Loew will join Alkermes in June as a strategic advisor and transition to CEO of Mural Oncology upon completion of the separation. 

Key Points: 
  • DUBLIN, June 1, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that Caroline J. Loew, Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc (Mural Oncology), the new independent public company to be established upon the planned separation of Alkermes' oncology business.
  • Dr. Loew will join Alkermes in June as a strategic advisor and transition to CEO of Mural Oncology upon completion of the separation.
  • "I'm delighted that we have appointed someone of Dr. Loew's caliber and scientific pedigree for the Mural Oncology CEO role.
  • Upon completion of the planned separation, Mural Oncology plc is expected to be a Nasdaq listed company, trading under the ticker symbol MURA.

Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases

Retrieved on: 
Tuesday, May 9, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Tissue, Graft-versus-host disease, Heart, SingHealth, Partnership, Boehringer, Doctor of Philosophy, Neoplasm, Infection, Survival, Pharmacokinetics, Quality of life, Scar, PDE4B, Inflammation, DSM-IV codes, Lung, Pulmonary fibrosis, Boehringer Ingelheim, Duke–NUS Medical School, Fibrosis, Death, Discovery, Patient, Vicki Belo, Circulatory system, Biology, Liver, IPF, Safety, Pharmaceutical industry

Boehringer Ingelheim is already a global leader in the treatment of pulmonary fibrosis, and the initiation of clinical development of the anti-IL-11 treatment reflects the company’s long-term commitment to combat fibrotic disease across therapeutic areas.

Key Points: 
  • Boehringer Ingelheim is already a global leader in the treatment of pulmonary fibrosis, and the initiation of clinical development of the anti-IL-11 treatment reflects the company’s long-term commitment to combat fibrotic disease across therapeutic areas.
  • The IL-11 inhibitor antibody is the first of its kind to reach clinical development stage and is based on a partnership between the Company and Enleofen Bio Pte.
  • ‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis, or scarring, of various organs and tissues.
  • Some examples of fibrotic diseases are, systemic sclerosis, graft-versus-host disease as well as heart, lung, liver, and kidney fibrosis.

BioSig Announces New Advisory Board Member Edwin Wang

Retrieved on: 
Monday, March 27, 2023
HarbourVest Partners, CalPERS, Columbia University, Foxconn, MIT Sloan School of Management, Cardiovascular disease, American Heart Association, Lehman Brothers, EJ, TSMC, The Deal (magazine), Public, Stroke, Medicine, CalSTRS, Advisory board, Credit Suisse, Wang, China Development Bank, Paul Capital, Publication, Investment, Circulatory system, Harvard Business School, Nobel, Nautilus, Inc. v. Biosig Instruments, Inc., AI, Death, Arrhythmia, PURE, Capital Group Companies, Security (finance), Economics

BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the appointment of new Advisory Board member Edwin Wang.

Key Points: 
  • BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the appointment of new Advisory Board member Edwin Wang.
  • Mr. Wang has over 20 years of impactful experience in private equity, venture capital, merchant banking, and family office investing.
  • Accretive Capital Partners has advised in excess of $2 billion in portfolio and fund restructurings.
  • )  BioSig Technologies leads the way forward in digital signal processing and AI for the treatment of cardiac arrhythmias.